See more : Anton Oilfield Services Group (ATONY) Income Statement Analysis – Financial Results
Complete financial analysis of TransMedics Group, Inc. (TMDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TransMedics Group, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Zanaga Iron Ore Company Limited (ZIOC.L) Income Statement Analysis – Financial Results
- New Gold Inc. (NGD) Income Statement Analysis – Financial Results
- Web To Door, Inc. (SPRV) Income Statement Analysis – Financial Results
- Luks Group (Vietnam Holdings) Company Limited (0366.HK) Income Statement Analysis – Financial Results
- ISDN Holdings Limited (1656.HK) Income Statement Analysis – Financial Results
TransMedics Group, Inc. (TMDX)
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 241.62M | 93.46M | 30.26M | 25.64M | 23.60M | 13.02M | 7.69M | 6.21M |
| Cost of Revenue | 87.53M | 28.19M | 9.10M | 9.00M | 9.74M | 7.28M | 5.55M | 5.44M |
| Gross Profit | 154.09M | 65.27M | 21.16M | 16.64M | 13.86M | 5.73M | 2.14M | 766.00K |
| Gross Profit Ratio | 63.77% | 69.84% | 69.92% | 64.88% | 58.73% | 44.05% | 27.81% | 12.34% |
| Research & Development | 63.27M | 26.81M | 22.30M | 18.83M | 19.87M | 13.66M | 14.96M | 15.64M |
| General & Administrative | 119.55M | 51.69M | 38.28M | 24.19M | 21.52M | 12.32M | 7.61M | 0.00 |
| Selling & Marketing | 0.00 | 18.21M | 8.60M | 931.00K | 2.07M | 1.02M | 674.00K | 0.00 |
| SG&A | 119.55M | 69.90M | 38.28M | 24.19M | 23.60M | 12.32M | 7.61M | 8.12M |
| Other Expenses | 0.00 | -1.00M | -877.00K | 1.65M | 790.00K | -213.00K | 548.00K | 5.00K |
| Operating Expenses | 182.82M | 96.71M | 60.59M | 43.02M | 43.47M | 25.97M | 22.56M | 23.75M |
| Cost & Expenses | 270.35M | 124.90M | 69.69M | 52.02M | 53.21M | 33.25M | 28.11M | 29.20M |
| Interest Income | 12.50M | 900.00K | 100.00K | 700.00K | 1.00M | 0.00 | 548.00K | 5.00K |
| Interest Expense | 10.79M | 3.73M | 3.87M | 3.99M | 4.35M | 2.42M | 1.07M | 979.00K |
| Depreciation & Amortization | 8.18M | 4.20M | 2.65M | 1.58M | 1.22M | 769.00K | 630.00K | 426.00K |
| EBITDA | -7.60M | -28.96M | -38.49M | -23.15M | -27.93M | -20.23M | -19.09M | -22.66M |
| EBITDA Ratio | -3.15% | -34.71% | -133.19% | -96.46% | -122.07% | -151.19% | -250.46% | -363.26% |
| Operating Income | -28.73M | -31.44M | -39.43M | -26.38M | -29.60M | -20.24M | -20.43M | -22.99M |
| Operating Income Ratio | -11.89% | -33.64% | -130.29% | -102.91% | -125.42% | -155.47% | -265.79% | -370.20% |
| Total Other Income/Expenses | 2.06M | -4.73M | -4.75M | -2.33M | -3.90M | -3.48M | -365.00K | -1.08M |
| Income Before Tax | -26.67M | -36.17M | -44.18M | -28.72M | -33.51M | -23.72M | -20.79M | -24.07M |
| Income Before Tax Ratio | -11.04% | -38.70% | -145.99% | -112.00% | -141.95% | -182.18% | -270.54% | -387.58% |
| Income Tax Expense | -1.64M | 66.00K | 36.00K | 32.00K | 40.00K | 41.00K | 32.00K | 984.00K |
| Net Income | -25.03M | -36.23M | -44.22M | -28.75M | -33.55M | -23.76M | -20.82M | -24.07M |
| Net Income Ratio | -10.36% | -38.77% | -146.11% | -112.13% | -142.12% | -182.50% | -270.96% | -387.58% |
| EPS | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -1.23 | -1.44 | -1.66 |
| EPS Diluted | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -1.23 | -1.44 | -1.66 |
| Weighted Avg Shares Out | 32.52M | 29.56M | 27.62M | 24.70M | 14.20M | 19.25M | 14.48M | 14.48M |
| Weighted Avg Shares Out (Dil) | 32.52M | 29.56M | 27.62M | 24.70M | 14.20M | 19.25M | 14.48M | 14.48M |
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass. , July 18, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 15, 2024, TransMedics...
TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024
ANDOVER, Mass. , July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results...
TransMedics (TMDX) Moves to Buy: Rationale Behind the Upgrade
TransMedics (TMDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
5 Growth Stocks Poised to Grow Faster than NVIDIA Next Year
In 2024, the fastest-growing stocks have been in the momentum category, led by NVIDIA (NASDAQ: NVDA).
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Vertex Pharmaceuticals could have multiple new blockbusters on the way. Viking Therapeutics is targeting two massive markets -- obesity and NASH.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass. , June 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on June 18, 2024, TransMedics...
The 3 Best Medical Device Stocks to Buy in June 2024
Medical devices are spearheading the digitalization of healthcare, reports analytics and software development company Luxoft. Specifically, medical devices are “providing accurate diagnoses, effective treatments and personalized care through advanced algorithms and patient data analysis.
Top 4 Health Care Stocks That May Keep You Up At Night This Month
As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
TransMedics (TMDX) Just Reclaimed the 20-Day Moving Average
TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX crossed above the 20-day moving average, suggesting a short-term bullish trend.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass. , May 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 14, 2024, TransMedics...
Source: https://incomestatements.info
Category: Stock Reports